Global healthcare companies are using the China International Import Expo (CIIE), which will last through Monday in Shanghai, to further connect local resources and foster China's healthcare ecosystem, with the aim of contributing to disease diagnosis and treatment.

French biopharmaceutical giant Sanofi announced the establishment of a type 1 diabetes ecosystem at its CIIE booth. This initiative, involving local hospitals, biotech firms and patient organizations, aims to advance clinical research, pilot early screening models, promote comprehensive disease management and enhance digital connectivity.

Sanofi's Tzield, the world's only drug to date to delay the onset of type 1 diabetes, is being highlighted at the company's booth following its approval for use in China in September. According to the company, the therapy can play a key role in shifting type 1 diabetes management in the country from reactive treatment to proactive intervention.

Sanofi, a regular CIIE participant, is also attempting to use the platform to foster collaboration with industry partners to enhance awareness of type 2 inflammation and build a diagnostic and treatment ecosystem.

The company's Dupixent is a targeted biologic that inhibits the primary driver of type 2 inflammation. Already approved in China for seven indications, Sanofi is now marketing Dupixent for its breakthrough potentials in two new indications in rhinology and dermatology.